| 1.86 0.02 (1.09%) | 05-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.58 | 1-year : | 2.97 |
| Resists | First : | 2.21 | Second : | 2.54 |
| Pivot price | 1.86  |
|||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.82 |
MA(20) : | 1.98 |
| MA(100) : | 2.38 |
MA(250) : | 2 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 21.2 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 3.65 | Low : | 0.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NMRA ] has closed above bottom band by 48.6%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.92 |
| Low: | 1.78 - 1.79 | 1.79 - 1.8 |
| Close: | 1.84 - 1.86 | 1.86 - 1.88 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Mon, 09 Mar 2026
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Yahoo Finance
Wed, 04 Mar 2026
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Yahoo Finance
Mon, 05 Jan 2026
New Alzheimer’s treatment candidate eases agitation in early study - Stock Titan
Mon, 27 Oct 2025
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model - Yahoo Finance
Thu, 24 Apr 2025
NMRA Stock Price, News & Analysis | Neumora Therapeutics - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 185 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 23.9 (%) |
| Held by Institutions | 55.9 (%) |
| Shares Short | 4,470 (K) |
| Shares Short P.Month | 4,960 (K) |
| EPS | -1.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.2 % |
| Return on Equity (ttm) | -121.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -206 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 3.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|